| Size | Price | |
|---|---|---|
| Other Sizes |
| Targets |
5-Bromopicolinonitrile is a synthetic intermediate and building block rather than a direct pharmacological agent. As a building block, it does not have specific biological receptors as its primary targets. The brominated pyridinecarbonitrile scaffold allows for various chemical transformations, including cross-coupling reactions and nitrile hydrolysis. It is used in the synthesis of aza-terphenyl diamidine analogs, which exhibit potent antiprotozoal activity. The compound's primary applications are as a synthetic intermediate for pharmaceuticals and agrochemicals.
|
|---|---|
| ln Vitro |
97483-77-7|Reference Standard for Tedizolid Impurity 13
In vitro, 5-bromopicolinonitrile is used as a biochemical reagent and organic compound for life science research. It is used in the synthesis of aza-terphenyl diamidine analogs, which exhibit potent antiprotozoal activity. Cellular assays are typically performed on the final compounds synthesized from this building block. The compound's brominated nitrile scaffold allows for various chemical transformations, making it valuable for drug discovery, particularly for antiprotozoal agents. |
| ln Vivo |
In vivo data for 5-bromopicolinonitrile is limited, as it is primarily a research reagent and synthetic intermediate. The compound is classified for research use only and is not intended for human or veterinary therapeutic applications. However, aza-terphenyl diamidine analogs synthesized using this building block have been investigated for their antiprotozoal activity. The compound's primary value lies in its use as a synthetic intermediate. Specific in vivo data for the parent compound is not available in the public literature.
|
| Enzyme Assay |
In vitro enzyme/receptor binding assays for 5-bromopicolinonitrile are not typically performed, as it is primarily a synthetic intermediate. The compound is used as a building block in the synthesis of aza-terphenyl diamidine analogs. A typical assay involves using the compound in chemical reactions, such as cross-coupling or nitrile functionalization, to prepare final compounds. The compound is dissolved in organic solvents such as DMSO or THF. The resulting products can be evaluated for biological activity. Antiprotozoal assays can be performed on the final synthesized compounds. IC₅₀ values are calculated from dose-response curves.
|
| Cell Assay |
Cellular assays for 5-bromopicolinonitrile derivatives typically evaluate antiprotozoal activity. A standard protocol involves culturing protozoan parasites (e.g., Leishmania, Trypanosoma) in appropriate growth medium. Parasites are treated with synthesized compounds at varying concentrations. Parasite viability and proliferation are assessed using microscopy, colorimetric, or fluorometric assays. Cytotoxicity is evaluated using mammalian cell lines. IC₅₀ values are calculated from dose-response curves. The compound's activity against protozoan parasites is compared to standard drugs.
|
| Animal Protocol |
In vivo animal studies for 5-bromopicolinonitrile are not standard, as it is a synthetic intermediate rather than a therapeutic candidate. The compound is classified for research use only and is not intended for human or veterinary applications. Any animal studies would typically be conducted on the final aza-terphenyl diamidine analogs synthesized using this building block. These studies would evaluate efficacy in animal models of protozoan infections, pharmacokinetics, and safety. The compound's primary value lies in its use as a synthetic intermediate.
|
| ADME/Pharmacokinetics |
Pharmacokinetic data for 5-bromopicolinonitrile is limited, as it is primarily a research reagent. The compound has a molecular weight of 183.01 g/mol and a molecular formula of C₆H₃BrN₂. It is a solid at room temperature with a melting point of 128-132°C. It is soluble in dichloromethane. As a brominated nitrile, it may undergo metabolic dehalogenation and nitrile hydrolysis. Specific ADME data is not available. The compound is stored in a dry, cool place.
|
| Toxicity/Toxicokinetics |
5-Bromopicolinonitrile is classified for research use only and is not intended for human or veterinary applications. Standard safety precautions include handling with appropriate personal protective equipment (gloves, lab coat, safety goggles) in a well-ventilated area. The compound should be stored in a dry, cool place away from incompatible materials. Acute toxicity data is not readily available in the public literature. As with all research chemicals, appropriate laboratory safety practices should be followed. No specific LD₅₀ values are available in the public domain.
|
| Additional Infomation |
5-Bromopicolinonitrile (5-Bromo-2-pyridinecarbonitrile, CAS 97483-77-7) is a biochemical reagent with the molecular formula C₆H₃BrN₂. It is characterized by a bromine atom and a cyano group on a pyridine ring and is used in the synthesis of aza-terphenyl diamidine analogs with antiprotozoal activity. The compound is classified as a research-use-only compound not intended for diagnostic or therapeutic purposes.
|
| Molecular Formula |
C6H3BRN2
|
|---|---|
| Molecular Weight |
183.01
|
| Exact Mass |
181.947
|
| CAS # |
97483-77-7
|
| PubChem CID |
817154
|
| Appearance |
Off-white to light yellow solid powder
|
| Density |
1.7±0.1 g/cm3
|
| Boiling Point |
260.3±20.0 °C at 760 mmHg
|
| Melting Point |
128-132 °C(lit.)
|
| Flash Point |
111.2±21.8 °C
|
| Vapour Pressure |
0.0±0.5 mmHg at 25°C
|
| Index of Refraction |
1.612
|
| LogP |
1.53
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
2
|
| Rotatable Bond Count |
0
|
| Heavy Atom Count |
9
|
| Complexity |
137
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
N#CC1C=CC(Br)=CN=1
|
| InChi Key |
DMSHUVBQFSNBBL-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C6H3BrN2/c7-5-1-2-6(3-8)9-4-5/h1-2,4H
|
| Chemical Name |
5-bromopyridine-2-carbonitrile
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 5.4642 mL | 27.3209 mL | 54.6418 mL | |
| 5 mM | 1.0928 mL | 5.4642 mL | 10.9284 mL | |
| 10 mM | 0.5464 mL | 2.7321 mL | 5.4642 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
